BPC-157 + TB-500 Australia — Batch-Verified Blend
From $79 AUD · ≥98% HPLC purity · third-party COA · ships Australia-wide
What is BPC 5mg + TB 5mg?
BPC 5mg + TB 5mg is a research blend of the pentadecapeptide BPC 157 with Thymosin Beta-4 fragment (TB-500), each at 5mg. BPC 157 is studied for angiogenesis and tissue-repair pathways, and TB-500 for actin sequestration, cell migration and angiogenesis. The blend is used as a reference material in preclinical regenerative and wound-healing models.
Specifications
- From: $79 AUD
- Category: Recovery & Repair
- Form: Lyophilised powder
- Purity: ≥98% HPLC
- Testing: Third-party Certificate of Analysis
- Classification: Research reference material · For Research Use Only
View full report ↗Report ID and verification key are redacted on our copy of this certificate. Request the unredacted report, or see the full CoA library.
This sample is quantified by assay mass — the laboratory did not report a purity percentage for it. Where a vial holds two peptides, each is measured separately and a single combined purity figure is not meaningful.
What the research covers
This vial contains two structurally unrelated research peptides co-lyophilised into a single cake, nominally 5 mg of BPC-157 and 5 mg of TB-500 (thymosin beta-4). They share no sequence homology and no proposed mechanism; they appear together because the preclinical literature has often used them in the same experimental models.
BPC-157 is a pentadecapeptide, sequence GEPPPGKPADDAGLV, molecular weight 1419.5 Da, corresponding to a partial fragment of a protein described in human gastric juice. Rodent studies have investigated it in gastrointestinal lesion models and in tendon, ligament, muscle and bone injury models, with proposed mechanisms in the literature including nitric oxide system modulation, effects on VEGFR2 signalling and angiogenic outgrowth, and interaction with focal adhesion kinase-paxillin signalling. The evidence base is overwhelmingly preclinical and concentrated in a small number of research groups.
Thymosin beta-4 is a 43-residue, N-terminally acetylated peptide of approximately 4963 Da and the major intracellular sequestering protein for monomeric G-actin. Through that actin-binding role it participates in regulating the cytoskeleton, and consequently in cell migration and motility. Research has examined it in angiogenesis, corneal and dermal wound-repair, and cardiac and neural injury models. Note that the name TB-500 is used in the industry both for full-length thymosin beta-4 and for the short Ac-LKKTETQ actin-binding fragment; the certificate analyte identifies which molecule is present.
Because the two peptides differ by roughly 3.5 kDa, they separate cleanly by reversed-phase HPLC and mass spectrometry, which is what makes independent per-component quantification possible. TXLABS supplies the blend as a laboratory reference material only. It is not an approved therapeutic good in Australia and is not supplied for human or veterinary administration.
Reading the certificate
Per-component assay is the defining requirement for a blend certificate. A single combined purity percentage is meaningless when a vial holds two different molecules, and any certificate presenting one for a blend should raise questions about what was actually measured. The two peptides here differ by roughly 3.5 kDa, so there is no analytical difficulty in resolving and quantifying them separately. Check also that the thymosin beta-4 component's observed mass identifies which TB-500 species is present. TXLABS publishes the Janoshik Analytical report in the CoA library: batch CS-t/b55-0108, tested 16 January 2026, reporting 5.80 mg of BPC-157 and 5.54 mg of TB-500 (TB4) against a 5 mg plus 5 mg label. The library marks it assay only rather than fabricating a purity figure.
Storage and handling
A two-peptide cake is stored on the terms of its less stable component, which here is the 43-residue thymosin beta-4 rather than the pentadecapeptide. Hold lyophilised material at -20 °C, desiccated and protected from light, and equilibrate the vial to room temperature before opening so that condensation does not wet the powder. Once diluent is added the two peptides share one solution and cannot be separated, so a single handling error affects both: introduce diluent gently down the vial wall, swirl rather than shake, keep the solution at 2-8 °C and protected from light, and aliquot before freezing rather than cycling one vial. The specific risk with a blend is silent ratio drift, since the longer peptide degrades faster and nothing visible signals the change. In Australian summer conditions, where letterboxes and delivery vehicles regularly exceed 40 °C, prompt collection and immediate refrigeration are the practical safeguards.
Working out concentration
For a blend, concentration must be recorded per component rather than as a total. The vial is nominally 5 mg BPC-157 plus 5 mg TB-500, 10 mg of peptide in all. Reconstituted with 2 mL of bacteriostatic water that gives 2.5 mg/mL of each peptide and 5 mg/mL of total peptide; with 1 mL it gives 5 mg/mL of each and 10 mg/mL total. Writing down only the total is the common error and it doubles the apparent concentration of either component. The reconstitution calculator will do the mass-over-volume arithmetic for any vial. These are worked concentration examples, not a protocol.
How it relates to adjacent compounds
Both components of this vial are stocked individually: BPC-157 in 10 mg and 20 mg vials, and TB-500 / thymosin beta-4 in 10 mg and 20 mg vials. Buying the blend rather than the singles is a question of experimental design and record-keeping, not chemistry, since the two molecules are identical whichever vial they arrive in. Within the same category, KPV appears in some overlapping gastrointestinal inflammation models but is a melanocortin-derived tripeptide with an entirely separate structural lineage. These are structural and mechanistic relationships only, not comparisons of effect. The choice between the blend and two single vials is a matter of experimental design, record-keeping and per-component traceability rather than of chemistry.